NeuroPace director granted shares and stock options

NeuroPace Inc director Uri Geiger reported new equity awards and updated holdings.

Rhea-AI Filing Summary

NeuroPace Inc director Uri Geiger reported new equity awards and updated holdings. He received a grant of 2,890 shares of common stock at no cost, bringing his directly held common shares to 17,748. These shares vest in twelve equal monthly installments, subject to his continuous service.

Geiger was also granted stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, expiring in 2036, which likewise vest in twelve equal monthly installments while he remains in service. Separately, 4,432,948 common shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power.

Insider Trade Summary

Grant/Award: 8,258 shares

Grant/Award 3 txns

Insider Geiger Uri

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,368	$0.00	$0.00
Grant/Award	Common Stock	2,890	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,368 contracts (Direct); Common Stock — 17,748 shares (Direct); Common Stock — 4,432,948 shares (Indirect, See footnote)

Footnotes (3)

1. F1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
2. F2. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.
3. F3. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Common stock grant: 2,890 shares Direct common shares after grant: 17,748 shares Stock options granted: 5,368 options +2 more

5 metrics

Common stock grant 2,890 shares Awarded to Uri Geiger; vests over 12 monthly installments

Direct common shares after grant 17,748 shares Direct NeuroPace holdings following the 2,890-share award

Stock options granted 5,368 options Right to buy NeuroPace common stock; vests over 12 months

Option exercise price $15.74 per share Strike price for 5,368 stock options expiring in 2036

Indirect common share holdings 4,432,948 shares Held by Accelmed Partners II LP with Geiger holding voting and dispositive power

Key Terms

Stock Option (Right to Buy), vesting, continuous service, dispositive power, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for 5,368 shares"

vesting financial

"The shares shall vest in twelve (12) equal consecutive monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service through each vesting date"

dispositive power financial

"has sole voting and dispositive power with respect to the shares held"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

indirect ownership financial

"Shares are held by Accelmed Partners II LP ... indirect holdings associated with Geiger"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NeuroPace (NPCE) director Uri Geiger report?

Uri Geiger reported equity awards from NeuroPace, including 2,890 shares of common stock and 5,368 stock options. These are compensation-related grants, not open-market purchases or sales, and vest over time based on his continued service with the company.

How many NeuroPace (NPCE) shares does Uri Geiger hold directly and indirectly?

After the reported awards, Geiger directly holds 17,748 NeuroPace common shares. In addition, 4,432,948 common shares are held indirectly through Accelmed Partners II LP, an investment entity for which he has sole voting and dispositive power over those shares.

What are the terms of Uri Geiger’s new stock option grant at NeuroPace (NPCE)?

Geiger received stock options for 5,368 NeuroPace common shares with a $15.74 exercise price per share and a 2036 expiration. These options vest in twelve equal monthly installments, conditioned on his continuous service with the company over the vesting period.

How do the new NeuroPace (NPCE) share grants to Uri Geiger vest?

Both the 2,890-share common stock grant and the 5,368-share option grant vest in twelve equal monthly installments. Vesting is contingent on Geiger’s continuous service with NeuroPace on each monthly vesting date until the awards are fully vested.

Were Uri Geiger’s NeuroPace (NPCE) transactions open-market buys or sells?

The reported NeuroPace transactions are grants and awards, not market trades. Geiger received 2,890 common shares and 5,368 stock options as compensation, both at no purchase price, so there were no open-market buying or selling activities disclosed here.

What entity holds NeuroPace (NPCE) shares indirectly associated with Uri Geiger?

4,432,948 NeuroPace common shares are held by Accelmed Partners II LP. Accelmed entities serve as general partners, and Geiger, as managing partner of Accelmed LLC, has sole voting and dispositive power over the shares held by Accelmed Partners II LP.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geiger Uri

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		2,890(1)	A	$0	17,748	D
Common Stock								4,432,948	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.74	06/05/2026		A		5,368		(3)	06/04/2036	Common Stock	5,368	$0	5,368	D

Explanation of Responses:

1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

2. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

3. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)